Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewBurden of pediatric hepatitis CPrevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of NepalImpact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies.Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infectionAssociation of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control studyPegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Clinical utility of pharmacogenomics in the management of hepatitis C.None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B.Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot studyImpact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis CUltra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirinLong-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation.Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma RiskPeginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.PharmGKB summary: peginterferon-α pathway.Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.
P2860
Q24628717-3651D331-8D3E-43A9-84BB-C9136ECC4E2EQ27025476-96D904BA-5307-46D6-A198-786F21E2D6B7Q28547151-3E9E2175-CAC8-416B-A133-9011E1CAF6ACQ28732828-97AA53A4-D966-4FC9-8BD3-2F0029525F3BQ30250088-D1B5DB3D-9748-492C-B290-904E7AE68484Q33559298-873F9199-7CEB-4560-B579-0005E1497719Q33572715-A0F7E626-E494-4E12-9FCA-2A5FB74D6131Q33765497-8E6FBAF0-E060-4E0D-B3BE-477396ED599AQ33783711-558F4826-72CA-419E-9256-CFAE8FE56049Q33807745-C1FEDCDC-AE71-4FED-8E83-FD36F9E2711AQ33867243-E0C8A4A0-F6D2-4ADF-B3D5-FCE94D8E719AQ33903850-47AD3EA1-E489-4D00-A5C9-ADCA2BF836E9Q34007851-A0DB9FA4-EF87-4122-89DC-041514DDEA85Q34429833-57B1689E-5330-4A96-A937-A7B215F7FDEAQ34464613-183B6CCC-D77E-4BB7-AAF2-5617674683D8Q34485088-8E7DC761-A0D2-4D39-A405-DF990D909E7AQ34532854-273A40E4-B583-4972-9D78-4E6002A61B68Q34539324-25F2CA62-CB16-4408-8D3D-6CA9D595A34EQ34604371-E21FE2B3-AD13-4C03-80B6-6D00F70BCF4DQ34612816-08613F28-4220-44B0-9912-A450072B76E8Q34634369-5EDB6E1D-117F-4067-97C1-32C85FA9A213Q34694441-A181BD70-B10E-4308-BBA0-AFFA2360FCBFQ35017075-2B3B73D9-CB49-42E9-A896-1783523DDC3DQ35122925-22949ACC-0F35-423B-A5D7-1EE9824BDB7AQ35226233-FBFA5BEA-DDBF-4D5D-962C-C5FB562976C4Q35529369-468EC77A-41F0-4543-966D-110EEE84CFA0Q35773677-E785B0CE-7116-44B9-9A5D-881F5D57633FQ35803105-9365F3EA-F8D6-4648-8A49-CA55AA37CA5CQ35812034-7FCB9550-76A8-4EC8-987E-D2CE80E13735Q35819595-2D2914C3-270E-415C-B529-6CE4F73EE82CQ35930570-1825CBC4-9D8E-423A-B0FF-BEB3215C7A35Q35947900-6F9B73D2-BF0E-4C11-AE10-9E5778566DE7Q36009124-51B74DEF-DB6E-4182-8506-DEA81F0E00DBQ36044806-DFF980D8-A695-4281-936A-FF3581C3F028Q36163864-A9D2CF1C-88AB-4A10-A4B8-2686F79F4C76Q36224697-46CBFE7A-19F9-4814-8E35-9C5651AAEF09Q36316508-6B2D6D8A-D2EC-49E0-B5DE-05E4822EC41CQ36501509-20ABB1B3-99BB-4180-9019-CFF04082BF3FQ36590755-B479504B-D920-46E2-A6AF-9541C8D29DE7Q36675098-BB0B90CE-335C-45E0-98ED-CD814DCBC2B8
P2860
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Role of interleukin-28B polymo ...... 2 infection in Asian patients.
@en
Role of interleukin-28B polymo ...... 2 infection in Asian patients.
@nl
type
label
Role of interleukin-28B polymo ...... 2 infection in Asian patients.
@en
Role of interleukin-28B polymo ...... 2 infection in Asian patients.
@nl
prefLabel
Role of interleukin-28B polymo ...... 2 infection in Asian patients.
@en
Role of interleukin-28B polymo ...... 2 infection in Asian patients.
@nl
P2093
P2860
P356
P1433
P1476
Role of interleukin-28B polymo ...... 2 infection in Asian patients.
@en
P2093
Chia-Yen Dai
Chung-Feng Huang
Jeng-Fu Yang
Liang-Yen Wang
Mei-Shin Wu
Ming-Lung Yu
Ming-Yuh Hsieh
Ning-Chia Chang
Shinn-Cherng Chen
Suh-Hang Hank Juo
P2860
P356
10.1002/HEP.23976
P407
P50
P577
2011-01-01T00:00:00Z